Expand CYBN Menu
CYBN MENU

CYBN Latest Press Releases

-- January 15, 2025 --

Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder Business Wire 12:07 PM

-- January 13, 2025 --

Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025 Business Wire 7:30 AM

-- January 9, 2025 --

Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 Business Wire 5:00 PM

-- December 10, 2024 --

Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results Business Wire 7:30 AM

-- December 4, 2024 --

Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024 Business Wire 7:30 AM

-- November 18, 2024 --

Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder Business Wire 7:00 AM

-- November 14, 2024 --

Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024 Business Wire 7:30 AM

-- November 13, 2024 --

Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results Business Wire 7:30 AM

-- October 31, 2024 --

Cybin to Participate at the 2024 Milken Institute Future of Health Summit Business Wire 7:30 AM

-- October 24, 2024 --

Cybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines Program Business Wire 7:30 AM

-- October 3, 2024 --

Cybin to Participate in Water Tower Research Fireside Chat on October 8, 2024 Business Wire 7:30 AM

-- October 1, 2024 --

Cybin Expands Clinical Team to Support CYB003 Phase 3 Program Business Wire 7:30 AM

-- September 27, 2024 --

Water Tower Research Publishes Initiation of Coverage Report on Cybin, Inc., "A Leader in Novel Neuropsychiatry Therapeutics" Globe Newswire 11:48 AM

-- September 24, 2024 --

Cybin to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit Business Wire 7:30 AM

-- September 19, 2024 --

Cybin Provides Corporate Update on Upcoming Clinical Milestones Business Wire 5:38 PM
Cybin Announces Completion of Previously Announced Share Consolidation Business Wire 7:26 AM

-- September 4, 2024 --

Cybin to Participate in the H.C. Wainwright 26th Annual Global Investment Conference Business Wire 7:55 AM

-- August 27, 2024 --

Cybin Announces Results of Annual and Special Meeting of Shareholders and Share Consolidation Business Wire 7:01 PM